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Abstract
Background: Although most outpatients are relatively healthy, many have chronic renal insufficiency, and high
override rates for suggestions on renal dosing have been observed. To better understand the override of renal
dosing alerts in an outpatient setting, we conducted a study to evaluate which patients were more frequently
prescribed contraindicated medications, to assess providers’ responses to suggestions, and to examine the drugs
involved and the reasons for overrides.
Methods: We obtained data on renal alert overrides and the coded reasons for overrides cited by providers at the
time of prescription from outpatient clinics and ambulatory hospital-based practices at a large academic health care
center over a period of 3 years, from January 2009 to December 2011. For detailed chart review, a group of 6
trained clinicians developed the appropriateness criteria with excellent inter-rater reliability (κ= 0.93). We stratified
providers by override frequency and then drew samples from the high- and low-frequency groups. We measured
the rate of total overrides, rate of appropriate overrides, medications overridden, and the reason(s) for override.
Results: A total of 4120 renal alerts were triggered by 584 prescribers in the study period, among which 78.2%
(3,221) were overridden. Almost half of the alerts were triggered by 40 providers and one-third was triggered by
high-frequency overriders. The appropriateness rates were fairly similar, at 28.4% and 31.6% for high- and low-
frequency overriders, respectively. Metformin, glyburide, hydrochlorothiazide, and nitrofurantoin were the most
common drugs overridden. Physicians’ appropriateness rates were higher than the rates for nurse practitioners
(32.9% vs. 22.1%). Physicians with low frequency override rates had higher levels of appropriateness for metformin
than the high frequency overriders (P =0.005).
Conclusion: A small number of providers accounted for a large fraction of overrides, as was the case with a small
number of drugs. These data suggest that a focused intervention targeting primarily these providers and
medications has the potential to improve medication safety.
Keywords: Medication safety, Clinical decision support system, Renal insufficiency, Drug prescribing, Chronic kidney
disease
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Adverse drug events due to dosing errors are common,
costly, and often preventable in patients with renal insuf-
ficiency [1,2]. In primary care settings, specifically,
chronic renal impairment is often discovered and diag-
nosed, and patients commonly have risk factors for
chronic kidney disease (CKD) such as age >65 years,
hypertension, cardiovascular disease, and diabetes melli-
tus [3-5]. The prevalence of CKD is growing most rap-
idly in people aged ≥60 years. According to the kidney
disease statistics in the United States, the prevalence of
CKD in people aged ≥ 60 years increased from 18.8% to
24.5%, as reported in the 1988–1994 National Health
and Nutrition Examination Survey (NHANES) study and
the 2003–2006 NHANES study [6]. Furthermore, many
patients with CKD are not appropriately diagnosed. A
previous study showed that completeness of patients’
problem list in terms of renal insufficiency in one net-
work was only 4.7%, which is lower than that for hyper-
tension, diabetes, and breast cancer [7]. This finding
suggests that their providers may not be aware of the
CKD in these patients, even though the glomerular fil-
tration rate (GFR) can be readily estimated from data
routinely available in the electronic health records. Auto-
mated clinical decision support (CDS) has shown promise
in reducing medication errors including improvement in
the frequency of appropriate dosing [6]. However, previous
studies have shown that providers override 50–80% of
alerts generated by renal decision support systems. [7-9]
These high override rates imply that either too many alerts
are being delivered or providers may be overriding clinic-
ally important suggestions. Some providers may be espe-
cially likely to override alerts, and thus, there is scope for
improvement.
We developed a renal alerting application first in inpa-
tients with renal insufficiency and showed that making
suggestions to providers improved the choices regarding
dose and frequency, and reduced the length of stay
among patients with renal insufficiency [8]. We subse-
quently applied this application to an outpatient setting.
Although we have extensively limited the drug coverage
to promote user acceptance, the fraction of prescriptions
deemed inappropriate was high [10].
Regarding the alert overrides, many are clinically jus-
tifiable, but many are likely inappropriate. It is uncer-
tain what the optimal override rate should be. Systems
should carefully consider which warnings they choose
to display. To better understand this issue, we aimed at
(1) identifying which providers more frequently pre-
scribe contraindicated medications, (2) assessing pro-
viders’ responses to renal alerts of CDS and how many
overrides were considered to be appropriate, and (3)
examining the drugs and reason(s) for rejecting advice
provided by the renal alert system.
Methods
A cross-sectional observational study design involving
retrospective medical chart review was used in this
study. This work was performed after acquiring permis-
sion from the IRB of Partners Healthcare.
Study setting
This study included 36 primary care practices affiliated
with Brigham and Women’s Hospital and Massachusetts
General Hospital, which are 2 teaching hospitals of the
Partners HealthCare System. A total of 1,718 prescribers
serve these sites.
The Longitudinal Medical Record (LMR) is a Partners-
developed electronic medical record that was implemented
in 2000. The LMR has CDS capability in the form of medi-
cation alerts for drug suggestions for patients with renal in-
sufficiency and provides 5 types of suggestions including
drug-drug interaction, drug-allergy, geriatrics, duplicate
therapy, and drug formulary. The LMR first determines
whether a patient has renal insufficiency, which is defined
as an estimated creatinine clearance (CrCL) of <50 mL/
min, by the Cockroft-Gault equation. Subsequently, based
on the real-time calculation of the estimated CrCL and the
drug prescribed, the LMR modifies the abovementioned
dose list, default dose amount, and default frequency.
The knowledge base was first developed approximately
15 years ago for an inpatient setting through literature
reviews and an expert panel including a nephrologist, a
pharmacist, and a general internist convened to review
all medication in the hospital’s drug formulary; medica-
tions that were renally cleared and/or nephrotoxic were
selected [8]. The knowledge base includes approximately
356 medications in 3 categories: mild (estimated GFR
[eGFR], 51–80 mL/min, 26 medications), moderate
(eGFR, 16–50 mL/min, 146 medications), and advanced
(eGFR, ≤15 mL/min, 184 medication). For the outpatient
setting, the mild category of renal insufficiency was inac-
tivated to decrease relatively unimportant alerts and in-
crease user adherence to alerts. The estimated CrCL was
calculated from weight and age, which were reported by
the nurse or physician, and the serum creatinine level as
per recent laboratory measurements. If renal insuffi-
ciency was detected and any medication was ordered,
the LMR modified one or more entities from among the
dose list, default dose amount, and default frequency.
Moreover, it showed the highlighted link introducing
substitute medications to guide a user (Figure 1). For ex-
ample, when a patient with estimated CrCL<30 mL/
min was prescribed hydrochlorothiazide, the “Alterna-
tives” link shows furosemide as an alternative drug.
Override appropriateness criteria
To set up the criteria for judgment of overriding appro-
priateness, a group of 6 trained clinicians consisting of
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We adopted a stepwise approach recommended by the
Kidney Disease: Improving Global Outcomes guidelines
of 2010 to improve drug dosing [11,12]. The stepwise
approach facilitates inclusion of multiple considerations
to achieve the desired goal in a timely manner for each
drug. Similarly, we considered multiple data in a step-
wise manner. First, we examined the values and trend of
eGFR or estimated CrCL for the last 6 months to deter-
mine if there was a steadily moderate or severe decrease
in renal function. Second, we reviewed electronic med-
ical records of demographics, history of disease, phys-
ician notes, and laboratory results to obtain evidence to
support the override reason(s) entered by a provider, i.e.,
to determine whether a patient has tolerated the drug in
the past, whether new evidence supports the type of
therapy, or whether a consultant was approached. Third,
we reviewed the medication history, monitored drug re-
sponses, and revised the regimen after assessing whether
substitute drugs were used before (Figure 2). The initial
criteria were modified iteratively until a consensus was
reached, with over 90% agreement for examination of a
sample of 50 randomly selected overrides.
Sampling and chart review
Among the override prescriptions, we limited the sam-
ples to providers with more than 20 alerts because of
the opportunity to override for 3 years. We randomly
sampled 300 warnings stratified by the prescribing pro-
vider’s override rate; 200 warnings from the providers
were categorized in the top 25 warnings with high-
frequency overrides and 100 warnings were taken from
the remaining providers. Using the override appropriate-
ness criteria, a researcher (I.C.) reviewed the LMR and
abstracted relevant information for 300 overrides from
the date the alert was triggered. Subsequently, each case
was reviewed by an attending physician (K.C.N.). The
final kappa value of inter-rater reliability was excellent
(0.93). Disagreements were resolved by discussion with
a third reviewer (D.W.B.). The reviewers were aware
that they could be reviewing frequent overriders, but
they did not know the override rates for individual
providers.
Outcomes
Our primary outcome was the rate of override appropri-
ateness, which indicates how many overrides could be
regarded as clinically justifiable. This outcome was calcu-
lated as the ratio of the number of appropriate overrides
to the total number of overrides. Our secondary outcomes
were the rate of appropriate overrides by provider type,
prescription type, drug type, and override reason(s). Alert
override rate and adherence rate were calculated based on
total alerts.
Figure 1 Example of the renal-dosing CDS function of the LMR. The “see details” link shows the value of estimated CrCL with relevant
information. The “Alternatives” link located in the upper portion of the screen displays the substitute drug list.
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We obtained renal alert override rates and the coded
reasons for overrides cited by providers at the time of
prescription from outpatient clinics and ambulatory
hospital-based practices over a period of 3 years, from
January 1, 2009 to December 31, 2011. All provider
types, including staff physicians, house staff, and nurse
practitioners, were considered non-physician providers
with prescribing authority.
Descriptive statistics were used to summarize the rates
of alert overrides and appropriateness. We compared the
appropriateness of overrides between sampling units and
provider types by drug and override reason. In the de-
tailed review of the 300 cases, we excluded redundant
cases (n=5), cases in which target medications were
cancelled later (n=4), and cases for which we could not
retrieve the electronic medical records (n= 2). Thus, 194
cases from the 200 samples and 95 from the 100 samples
were analyzed. Data are presented as numbers with
percentages, and P values were calculated using the Chi-
square test. We used SAS 9.3 software (SAS Institute,
Cary, NC, USA) for data analyses.
Results
Incidence of renal alerts and overrides
For the 3-year period, total alerts triggered were 197,288,
by 1,718 prescribers along with all types of medication in
the CDS system, which included renal alerts. Among the
alerts, 4,120 were renal alerts and were triggered by 584
prescribers (34% of all prescribers), and 3,221 (78.2%) were
overridden (Figure 3). Among the prescribers, 544 (93.2%)
had triggered ≤20 alerts. This group had an average over-
ride rate of 70%. The remaining 40 providers (6.8%) had
triggered >20 alerts and had triggered almost half of the
renal alerts, with a 90.5% override rate. On classifying the
providers into the top 25 overriders (high-frequency overri-
ders) and the remaining overriders (low-frequency overri-
ders), the override rates were 95.0% and 78.9%, respectively.
Figure 2 Criteria of judgment of appropriateness for renal alert override. CrCL: creatinine clearance.
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Based on the override appropriateness criteria, the elec-
tronic medical records of 289 override samples by 35 pro-
viders were examined. Of 289 overrides, 85 (29.4%)
prescriptions were considered appropriate (Table 1). Low-
frequency overriders showed a slightly higher appropriate-
ness rating than high-frequency overriders. Most of the
appropriate overrides were for prescriptions given for a
temporal drop or fluctuation in the CrCL value below a
specific drug’s threshold (e.g., 50 mL/min for metformin
and 30 mL/min for hydrochlorothiazide) or reference
CrCL value, which was on the borderline. In some cases,
the CrCL values were missing from the LMR; therefore,
referenced eGFR values were used instead of CrCL values.
For 11 overrides, providers had tried to use substitute
drugs or initiated drugs with minimum doses.
We compared the proportion of appropriate overrides
by provider type (Table 2) and found that 5 prescribers
were physician assistants who entered 39 medication
prescriptions in the top 25 samples. We excluded them
because we were not sure whether the physician assis-
tants’ supervising physician(s) saw the alerts directly and
responded to them. A physician assistant might ask the
physician whether there was an alert and how to re-
spond it. Considering the relationship between the phys-
ician and the assistant regarding entering prescriptions
into system, it is not plausible for a physician to read the
information on the alert by himself/herself. We further
looked into 250 prescriptions entered by 21 physicians
and 9 nurse practitioners to compare the rates. Staff
physicians (n=20) and house staff (n =1) showed a
higher proportion of appropriate overrides (33%) than
nurse practitioners (22%). On categorizing the overrides
by drug, glyburide showed the highest number of appro-
priate overrides, followed by hydrochlorothiazide, met-
formin, nitrofurantoin, and the others. On categorizing
by prescription type, renewal medications were more
likely to be overridden and showed higher appropriate
overrides than new medications.
Figure 3 Breakdown of alert and override frequency by prescribers.
Table 1 Frequency of overrides and appropriate
overrides by provider group
Frequency (%)
Prescription
provider group
Overridden
alerts
Appropriate
overrides
Inappropriate
overrides
High frequency
over-riders (n=25)
194 (100.0) 55 (28.4) 139 (71.6)
Low frequency
over-riders (n=10)
95 (100.0) 30 (31.6) 65 (68.4)
Total 289 (100.0) 85 (29.4) 204 (70.6)
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chose the “patient has tolerated this drug in the past”
option to reason the override alert. As such, the trend of
CrCL or eGFR values for the last 6 months should was
stable over the moderate category. However, sometimes,
it was difficult to find such evidence in the chart review,
which was similar for cases of both appropriate and in-
appropriate overrides. For example, the 8 prescriptions
in which physicians selected the “new evidence supports
therapy of this type” as an override reason were judged
as appropriate because the CrCL values were maintained
around the threshold or the physicians had used a sub-
stitute drug first or minimum-dose approach at initi-
ation. For the “other” category option, no additional text
was entered.
On comparing provider groups by drug, physicians
who were low-frequency overriders showed significantly
higher override appropriateness than physicians who
were high-frequency overriders for metformin (Table 3).
For hydrochlorothiazide, the physicians of the high-
frequency overriders were more accurate in their deci-
sion than the low-frequency overriders, although this
difference was not significant. Glyburide showed the
highest appropriateness rate of 80%.
Evaluation of the proportion of appropriateness by
prescription types showed no significant differences
(Table 4). Renewal medications of physicians were more
frequently overridden and appropriate than the new
medications. On comparison of provider groups, physi-
cians who were low-frequency overriders had higher ap-
propriateness than those who were high-frequency
overriders. Among nurse practitioners, no appropriate
override was noted for a new medication.
Discussion
In our study, one of every 3 renal alerts was triggered by
high-frequency overriders who also overrode alerts more
often than those who received fewer alerts. Overall,
approximately 30% of the overrides were appropriate for
both physicians and nurse practitioners. Only 3 drugs—
metformin, hydrochlorothiazide, and glyburide—accounted
for the majority of overridden prescriptions.
Our findings show a slightly different perspective to the
noncompliance problem of renal-dosing guidelines and
promote a CDS approach to reduce kidney-related drug-
Table 2 Rates of appropriate override by provider type,
drug type, prescription type, and override reason(s)
No. of appropriate overrides/no.
of overridden alerts (%)
Physicians
(n=21)
Nurse
practitioners
(n=9)
Total
Drug type
Metformin 25/79 (31.6) 11/37 (29.7) 36/116
(31.0)
HCTZ 18/50 (36.0) 5/16 (31.3) 23/66
(34.8)
Glyburide 12/26 (46.2) 1/8 (12.5) 13/34
(38.2)
Nitrofurantoin 2/12 (16.7) 0/14 (0.0) 2/26
(7.7)
Others
† 0/6 (0.0) 0/14 (0.0) 0/20
(0.0)
Prescription types
New 2/23 (8.7) 0/21 (0.0) 2/43
(4.7)
Renew 55/150 (36.7) 17/56 (30.4) 72/201
(35.8)
Override reasons
Patient has tolerated this drug
in the past
43/123 (35.0) 15/57 (26.3) 58/180
(32.2)
New evidence supports
therapy of this type
8/18 (44.4) 0/2 (0.0) 8/20
(40.0)
Advice from a consultant 1/1 (100.0) 0/2 (0.0) 1/3
(33.3)
Other
‡ 5/31 (16.1) 2/16 (12.5) 7/47
(14.9)
Total 57/173 (32.9) 17/77 (22.1) 74/250
(29.6)
HCTZ, hydrochlorothiazide. Others
† includes acetylsalicylic acid, and
combination of aspirin and oxycodone. Other
‡ indicates a category.
Table 3 Comparison of appropriate override rates between provider groups by drug
Provider
drug
No. of appropriate overrides/no. of overridden alerts (%)
Physicians (n= 21) Nurse practitioners (n=9)
High frequency
overriders
Low frequency
overriders
χ
2 (P)
† High frequency
overriders
Low frequency
overriders
χ
2 (P)
†
Metformin 11/53 (20.8) 14/26 (53.9) 8.83 (0.0046) 7/20 (35.0) 4/17 (23.5) 0.58 (0.4951)
HCTZ 14/34 (41.2) 4/16 (25.0) 1.24 (0.3510) 2/7 (28.6) 3/9 (33.3) 0.04 (1.000)
Glyburide 8/21 (38.1) 4/5 (80.0) 2.85 (0.1478) 1/5 (20.0) 0/3 (0.0) 0.69 (1.000)
Nitrofurantoin 1/6 (16.7) 1/6 (16.7) 0.0 (1.000) 0/7 (0.0) 0/7 (0.0) 0.0 (1.000)
Other
† 0/2 (0.0) 0/4 (0.0) 0.0 (1.000) 0/12 (0.0) 0/2 (0.0) 0.0 (1.000)
Total 34/116 (29.3) 23/57 (40.4) 2.11 (0.1465) 10/39 (25.6) 7/38 (18.4) 0.58 (0.5843)
HCTZ, hydrochlorothiazide. Other
† includes acetylsalicylic acid, and combination of aspirin and oxycodone.
†Indicates a Fisher’s exact test.
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works, reporting the eGFR with other measures of kid-
ney function has been no effect on improving the
compliance, and a wide availability of drug-dosing
guidelines was not sufficient [13]. As current studies
have repetitively reported, the frequency of excess dos-
ing of kidney disease-related drugs in older patients
with CKD in an ambulatory setting is still high [5,13].
Such noncompliance problems are similar to those seen
in hospitalized patients and residents of long-term care
facilities [14,15]. A CDS system approach was regarded
as a new tool to provide the necessary framework to re-
duce inappropriate drug prescription. However, the
CDS system alone might not be sufficient. In a previous
study on the effects of a CDS system in patients with
renal insufficiency, Chertow et al. found that despite
the overall improved appropriateness of dosing, 49% of
medication orders were still inappropriate in the inter-
vention group [8].
Studies that reported successful effects of a CDS sys-
tem for patients with renal insufficiency showed similar
limitations. One study [16] revealed an improvement in
many aspects of prescription including improved fre-
quency of administration and lower rates of orders for
drugs that should be avoided. However, the system did
not improve the rate at which physicians ordered ap-
propriate doses for residents with renal insufficiency.
On comparison by alert type, appropriate orders ranged
from 41–75% in the CDS intervention group; inappro-
priate orders still accounted for 25–49% of the total or-
ders. Another study [17] reported that a CDS approach
decreased the likelihood of a patient receiving at least
one dose of a contraindicated drug, but the patients
still had a 47% chance of being prescribed a contraindi-
cated drug. Regarding the limitations of CDS, some
physicians may have been reluctant to reduce the drug
dosages, and others may have simply disregarded the
advice, favoring their own established practice patterns.
In the present study, we could depict really they are
and be relatively small number as high overriders. If we
could approach and intervene them, we could improve
the noncompliance problemoverall. In other words,
physician-level targeted interventions might be helpful
to improve high override rates if the physicians can be
assured of the importance of the warnings.
With regard to override appropriateness, little data on
renal suggestion alerts are available. On comparing the
override appropriateness of other alert types, the rate re-
ported in the present study (29.4%) was lower than that
of override appropriateness of drug interactions in our
previous work (63%) [18] and of drug interaction and
drug allergy in another previous study (63.5%) [1]. These
differences should be considered owing to the relatively
clear rules about renal insufficiency by drugs. McCoy
et al. [19] presented a framework using the matrix of
alertness displayed and provider response. They defined
the rate of inappropriateness as the ratio of the number
of inappropriate responses to the total number of alerts.
However, in the current study, we focused on providers’
appropriate override rather than appropriate alerts. The
rate of inappropriateness was calculated as the ratio of
the number of unjustifiable overrides to the number of
total overrides. The unjustifiable overrides were those
that were judged as clinically unacceptable by the over-
ride appropriateness criteria. Based on the rate of appro-
priate overrides, we can expect that a decrease of
approximately 30% in the override rates would indicate
reasonable improvement in providers’ decision-making.
For the borderline cases, it would be helpful to inform
providers about the variations and trends in CrCL or
eGFR. Regarding the subgroup analysis by provider type,
physicians’ rates of appropriate overrides were higher
than those of nurse practitioners with regard to drug
type, prescription type, and override reason(s). This im-
plies that more support is needed for nurse practitioners.
In addition, more awareness about the appropriate use
of metformin, hydrochlorothiazide, and glyburide is
needed. As Huang et al. [20] reported, CKD was com-
mon in older adults prescribed metformin for type 2 dia-
betes, and this is a growing concern for potentially
inappropriate medication use.
Our findings were consistent with those of previous
studies, which reported override rates ranging from 40%
to >80% with CDS for nephrotoxic or renally cleared
medications in various settings [7,17,21]. The override
rate in the present study (78.2%) was relatively higher
Table 4 Comparison of appropriate override rates between provider groups by prescription type
Provider
prescription
type
No. of appropriate overrides/no. of overridden alerts (%)
Physicians (n= 21) Nurse practitioners (n=9)
High frequency
overriders
Low frequency
overriders
χ
2 (P)
† High frequency
overriders
Low frequency
overriders
χ
2 (P)
†
New 1/16 (6.3) 1/7 (14.3) 0.40 (0.5257) 0/12 (0.0) 0/9 (0.0) 0.0
Renew 33/100 (33.0) 22/50 (44.0) 1.74 (0.1875) 10/27 (37.0) 7/29 (24.1) 1.10 (02942)
†Indicates a Fisher’s exact test.
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patient settings and the emergency department [14,17].
One study showed physicians overrode 59.4% of alerts,
recommending that a drug be avoided [14]. Another
study reported a 43% overdosing rate after implementa-
tion of CDS alerts [17]. McCoy et al. [22] observed that
in 78.1% of the cases, providers initially deferred inter-
ruptive alerts indicating contraindicated or high-toxicity
medications. Using the same medication dosing system
as in the present study, Chertow et al. demonstrated that
inappropriate prescription rates decreased to 33% and
41% by dose and frequency, respectively, for inpatients
with renal insufficiency [8]. Our current override rate,
which is higher, suggests that the number of alerts that
our providers experienced has increased, which could
lead to alert fatigue.
There are three possible reasons for this high override
rate. First, the override rate may differ depending on the
clinical setting. Outpatients might be tend to be older
and have chronic diseases such as hypertension or/and
diabetes compared to inpatients of acute care. We noted
that the major drugs overridden were hypertension and
diabetes medications, which accounted for 86% of the
overridden drugs. We also found that a small number of
drugs were overridden repetitively over patients; this
finding was limited to outpatients, and metformin or hy-
drochlorothiazide was the most commonly overridden
drugs in other settings. Previous studies have reported
various drug lists involved in overriding alerts. To our
knowledge, the current study is the first to report on
the use of renal suggestions in an outpatient setting.
Therefore, we need more studies to elaborate on this
difference in varied settings. Second, it is possible that
high-frequency overriders substantially contributed to
the increase override rate. Third, a crude increase in
the number of alerts due to addition of new alert types
over time on the computerized physician order entry
systems or known drugs requiring alerting could in-
crease the total number of alerts. Over the years, the
alerts displayed have been undergoing revision, and
more low-yield warnings may have been added [23].
Considering renal suggestions only, the alert thresholds
for outpatients were adjusted higher than that for mild
renal insufficiency (estimated CrCL, 50–80 ml/min). In
addition, when we examined whether the top 25 high
overriders overlapped with the high-frequency overri-
ders of other types of alerts, we found that more than
two-thirds overlapped with the high-frequency overri-
ders of geriatrics, drug interactions, and drug-allergy
types. This implies that the effect of a crude increase in
the number of alerts is considerable.
Regarding the reasons cited by providers, we found the
coded reason(s) were not used accurately by providers and
did not reflect any clinical context. This finding was
similar to that of our previous work on drug interaction,
wherein we found that only one-third of the providers
overrode according to override reason(s) and sometimes,
we had no evidence to confirm the reason(s) [18]. The list
of coded reason(s) might not be suitable for delivering
clinical context or providers simply believe that choosing
an accurate reason was not important. Our findings sug-
gests that organizations should consider periodically
reviewing the reasons selected for overrides—if providers
know that someone is evaluating this information, they
may be more likely to provide accurate information. In
order to account for these override reason(s) while ex-
trapolating override appropriateness and while setting up
a management goal, collecting data correctly is important.
Our study has several limitations. First, it was under-
taken within a single academic health care center using
one outpatient-prescribing system, and the results may
not be generalizable to other prescribing systems. Never-
theless, the findings have important implications for en-
hancing medication safety and identifying an approach
to decrease high override rates. Second, we did not
evaluate the appropriateness by patient and could not
follow up patients’ results of inappropriate overrides.
However, inappropriate overrides reflect, to some extent,
medication errors that accompany kidney disease, which
can affect every organ system and every aspect of drug
disposition.
Conclusions
The outpatient setting includes the elderly and many pa-
tients with chronic diseases, i.e., groups that are especially
vulnerable to inappropriate medication dosing and drugs.
Overall, 3 of 10 overrides were regarded as clinically justi-
fiable. A small number of providers accounted for a large
proportion of overrides, and they nearly always overrode
inappropriately. These data suggest that a provider-level
intervention might successfully improve medication safety
in this group of patients.
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